Evidence map›Paper›PMID 31570001›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2019

Estrogen-related receptor β activation and isoform shifting by cdc2-like kinase inhibition restricts migration and intracranial tumor growth in glioblastoma.

Deanna M Tiek, Subreen A Khatib, Colin J Trepicchio, Mary M Heckler, Shailaja D Divekar, Jann N Sarkaria, Eric Glasgow, Rebecca B Riggins

Open access · greenAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. RNA modifications in brain tumorigenesis.Acta neuropathologica communications · 2020
    Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Deanna M TiekDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Subreen A KhatibDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Colin J TrepicchioDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Mary M HecklerDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Shailaja D DivekarDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Jann N SarkariaDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Eric GlasgowDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Rebecca B RigginsDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Georgetown University Medical Center · USGeorgetown University · USMayo Clinic · USNational Cancer Institute · US

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI Louis M Weiner · 1990 to 2026
$71.5M
Targeted MV-CEA as a Potent Antitumor Agent against GBMP50CA108961 · NCI · MAYO CLINIC ROCHESTER · PI O'NEILL, BRIAN PATRICK · 2004 to 2015
$22.5M
TRAINING GRANT IN TUMOR BIOLOGYT32CA009686 · NCI · GEORGETOWN UNIVERSITY · PI ANNA Tate RIEGEL, DAVID J ROBBINS · 1996 to 2026
$10.8M
Mitotic Regulation by the ERRbeta2 Splice VariantR21CA191444 · NCI · GEORGETOWN UNIVERSITY · PI RIGGINS, REBECCA B · 2014 to 2015
$372k
Novel relationships of splicing factors in temozolomide-resistant glioblastomaF99CA234799 · NCI · GEORGETOWN UNIVERSITY · PI TIEK, DEANNA MARIE · 2018 to 2018
$34k
NCI NIH HHS F99 CA234799NCI NIH HHS P30 CA051008NCI NIH HHS P50 CA108961NCI NIH HHS R21 CA191444NCI NIH HHS T32 CA009686
6 · The paper itself

Abstract

Glioblastoma (GBM; grade 4 glioma) is a highly aggressive and incurable tumor. GBM has recently been characterized as highly dependent on alternative splicing, a critical driver of tumor heterogeneity and plasticity. Estrogen-related receptor β (ERR-β) is an orphan nuclear receptor expressed in the brain, where alternative splicing of the 3' end of the pre-mRNA leads to the production of 3 validated ERR-β protein products: ERR-β short form (ERR-βsf), ERR-β2, and ERR-β exon 10 deleted. Our prior studies have shown the ERR-β2 isoform to play a role in G

Indexed as

Cell MovementActin CytoskeletonAnimalsApoptosisBiomarkers, TumorBrain NeoplasmsCell CycleCell ProliferationDrug Therapy, CombinationGene Expression Regulation, NeoplasticGlioblastomaHumansHydrazinesProtein IsoformsProtein Serine-Threonine KinasesProtein-Tyrosine KinasesBiomarkers, TumorClk dual-specificity kinasesESRRB protein, humanHydrazinesN'-((1E)-(4-(diethylamino)phenyl)methylene)-4-hydroxybenzohydrazideProtein IsoformsProtein Serine-Threonine KinasesProtein-Tyrosine KinasesReceptors, EstrogenTG 003Thiazolesalternative splicingCLKcortactinERR-βGBM

Identifiers

PMID31570001
PMCPMC6894094
OpenAlexW2979013045

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.